Asahi Kasei Pharma begins phase III study of promising CIPN prevention therapy, Recomodulin to enhance treatment options worldwide: Chelmsford, Massachusetts Thursday, July 3, 202 ...

CHELMSFORD, Mass. & NOVI, Mich. & DÜSSELDORF, Germany & TOKYO, July 02, 2025--Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan for CIPN.

A rise in the number of B6 toxicity cases across the nation has sparked action by the TGA to move products behind pharmacy counters.

The Global Neuropathic Pain Market is valued approximately at USD 8.14 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.73% over the forecast period 2024-2032.

TMC207 is a first-in-class anti-TB diarylquinoline (also named R207910 or the 'J' compound) with activity against drug-sensitive and drug-resistant TB. TMC207 inhibits the proton pump of ...

A newly approved Alzheimer’s drug is set to be administered for the first time in Taiwan on Monday, Far Eastern Memorial Hospital in New Taipei City announced yesterday. Kisunla, the brand name of the ...

JACKSON, Miss. (WLBT) -A new breakthrough drug for HIV Prevention has been approved by the FDA. The drug is called “Yeztugo” and only needs to be injected twice a year to prevent HIV. Although the ...

Scientists are to examine whether drugs that are already in use could be repurposed to treat the symptoms of both Alzheimer’s disease and Parkinson’s in a new collaboration which aims to ...

It comes after the NHS spending watchdog rejected the use of new Alzheimer’s drugs lecanemab and donanemab for widespread use in the health service. The drugs were approved for use in the UK last year ...